Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters

  • Pedreño López, Núria|||0000-0001-6927-2301
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Usai, Carla|||0000-0002-6373-2765
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Benet, Susana|||0000-0002-2219-8826
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Carabelli, Julieta|||0000-0003-2329-3996
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Avila-Nieto, Carlos
  • Roca, Núria
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pérez, Mònica
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Matilla, Marina
  • Revollo, Boris|||0000-0001-9245-2183
  • Hernández, Agnes
  • Abad Capa, Jorge|||0000-0002-8129-7859
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Moltó, Jose
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Massanella, Marta|||0000-0002-3326-151X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Blanco, Julià|||0000-0002-2225-0217
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Carrillo, Jorge|||0000-0003-0221-5948
Severe COVID-19 associates with humoral immune response dysregulation. While antibodies confer protection against SARS-CoV-2, evidence also support their putative contribution to disease severity. Our study demonstrates that higher levels of S2-IgG, and S2-, RBD-, and Nucleocapsid-IgA differentiate severe and non-severe cases. However, no major antibody functional differences are found between both COVID-19 manifestations. Enhanced Fc-dependent functions in severe cases are primarily driven by increased antibody titers. No differences in antibody avidity are found between severe and non-severe cases, but a gradation in binding strength across specificities suggests that early anti-RBD, -S2, and -Nucleocapsid antibodies may originate from different pathways. In golden Syrian hamsters, S2 immunization or transfer of RBD-depleted antibodies isolated from severe and non-severe cases promote a faster clinical recovery after SARS-CoV-2 challenge, despite a transient initial weight loss. These findings indicate that antibodies are not major determinants of COVID-19 severity and suggest additional factors influencing disease outcomes. Functional analysis of antibody responses against SARS-CoV-2 shows their role in the development of SARS-CoV-2-induced severe disease in golden Syrian hamsters.